Compare BioNano Genomics Inc (BNGO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Omnicom Group Inc. — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.77M), while Omnicom Group Inc. trades at $86.41 (market cap $23.46B). The key difference: Omnicom Group Inc. is far larger — about 1703.7× BioNano Genomics Inc's market cap, and Omnicom Group Inc. pays a 3.74% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | OMC | |
|---|---|---|
Market Cap | $13.77M | $23.46B |
Sector | Health | Media |
52-Week High | $4.92 | $86.22 |
52-Week Low | $1.06 | $67.27 |
Enterprise Value | $16.38M | $31.53B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Omnicom Group (OMC) trades at $85.45, up 0.95% with a bullish technical outlook and strong institutional support. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Recent acquisition of Interpublic Group has driven 6.1% organic revenue growth and margin expansion, though 2025 saw a net loss of $54.5 million. Analyst consensus price target stands at $107 with 32% buy ratings.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.97) and 4% dividend yield, supported by post-merger synergies and strong cash flow generation. Key risks include integration challenges from the Interpublic acquisition, competitive pressures in advertising services, and debt levels following the merger. The stock's current price offers 25% upside to consensus targets with institutional accumulation signaling confidence in the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
